New award for rituximab with pfizer INC. Base year ordering period is september 15, 2025 to september 14, 2026 with four one-year options.
Active Indefinite Delivery Contract Awarded Last action
- Contract number
- 36E79725D0032
- Awardee
-
Pfizer Inc. UEI MHBQULRMEEJ5
- Awarding agency
-
National Acquisition Center
Headquarters, Department of Veterans Affairs
- Task orders
- 0
Award facts
- Opportunity
-
- 6505--Rituximab and Biosimilars Pre-Solicitation · 36E79725R0021 · Posted Jan 28, 2025
- Last date to order 56% complete
- IDV ceiling
- $74,038,216.80
- Award type
- Single award
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 2 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
Award details come from SAM.gov/FPDS.
About this IDV
The VA National Acquisition Center awarded an indefinite-delivery contract to Pfizer Inc. for Rituximab and its biosimilars on September 15, 2025, with a ceiling value of $74,038,216.80. This is a single-award contract with no set-aside category.
The contract serves multiple federal healthcare agencies including the Department of Veterans Affairs, Department of Defense, Bureau of Prisons, Indian Health Service, and Federal Health Care Center. Place of performance encompasses these agencies' facilities nationwide.
The originating solicitation (36E79725R0021) sought an uninterrupted supply of Rituximab and FDA-licensed biosimilars, with estimated annual requirements of 17,858 vials of 10 mL product and 25,111 vials of 50 mL product. Offerors were required to provide exact drug names as labeled and unique NDC numbers; all proposed biosimilars had to be FDA-licensed under 42 U.S.C. Section 262 and listed in the FDA Purple Book. The procurement was conducted under FAR Part 12 for commercial product acquisition.
The contract runs from September 15, 2025, through September 14, 2026 (base year), with four one-year option periods extending the potential performance through September 14, 2027. Work is categorized under NAICS 325412 (Pharmaceutical Preparation Manufacturing).
The contract was modified in April 2026 to incorporate Section 5 of Executive Order 14398, Clause 52.222-90, addressing diversity, equity, and inclusion discrimination prohibitions for federal contractors.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $0 | |
| Add Subcontract Plan | $0 | |
| Other Administrative Action | $0 | |
| Original award | $0 |
Quick answers
Who was awarded contract 36E79725D0032?
36E79725D0032 was awarded to Pfizer Inc. by National Acquisition Center (Headquarters) on September 15, 2025.
How much is contract 36E79725D0032 worth?
36E79725D0032's own ceiling is $74,038,217.
Who can order from contract 36E79725D0032?
36E79725D0032 is a single award indefinite delivery contract.
Was contract 36E79725D0032 competed?
The extent of competition for 36E79725D0032 was full and open competition. The government received 2 offers.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV